Accuray Incorporated (ARAY)
| Previous close | 2.2200 |
| Open | 2.2100 |
| Bid | 2.1800 x 100 |
| Ask | 2.1900 x 100 |
| Day's range | 2.1800 - 2.2250 |
| 52-week range | 2.1000 - 4.3000 |
| Volume | |
| Avg. volume | 489,043 |
| Market cap | 216.684M |
| Beta (5Y monthly) | 1.47 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1500 |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.75 |
PR NewswireAccuray Expands Global Training Center Network With Opening of New Facility in Genolier, Switzerland
Accuray Incorporated (NASDAQ: ARAY) announced today that as part of its commitment to advancing patient care the company has opened a new training center in Genolier, Switzerland, that will serve as the European education hub for radiosurgery and radiotherapy product training, and sharing of best practices and innovative techniques using the latest model Accuray CyberKnife® and Radixact® Radiation Treatment Delivery Systems and Accuray Precision® Treatment Planning System. The Genolier based cen
PR NewswireAccuray to Report Third Quarter Fiscal 2024 Financial Results on May 1, 2024
Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2024, ended March 31, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on May 1, 2024.
ZacksAtossa (ATOS) Reports Positive Results From EVANGELINE Study
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.
